This inventor holds 2 USPTO granted patents and 5 published patent applications and 2 EPO patents. Top assignee: Glaxo Group Limited. Active years: 2014-2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014-2015
Title: David Francis Tough: Innovator in Autoimmune and Inflammatory Disease Treatment
Introduction
David Francis Tough is a notable inventor based in Stevenage, GB. He has made significant contributions to the field of medicine, particularly in the treatment of autoimmune and inflammatory diseases. With a total of 2 patents, his work has the potential to impact therapeutic approaches for various conditions.
Latest Patents
David's latest patents include innovative methods for treating autoimmune and inflammatory diseases. One patent focuses on inhibitors of SP140, which involves a method of treating such diseases in mammals, including humans, through the administration of an inhibitor of the bromodomain-containing protein SP140. Another patent details a method of treatment based on ATAD2 inhibitors, which also targets autoimmune and inflammatory diseases by administering an inhibitor of the bromodomain-containing protein ATAD2.
Career Highlights
David is currently associated with Glaxo Group Limited, where he continues to advance his research and development efforts. His work is characterized by a commitment to improving therapeutic options for patients suffering from complex diseases.
Collaborations
Some of David's notable coworkers include Kevin Lee and Laurens Kruidenier. Their collaborative efforts contribute to the innovative research environment at Glaxo Group Limited.
Conclusion
David Francis Tough is a dedicated inventor whose work in the field of autoimmune and inflammatory disease treatment showcases his innovative spirit and commitment to improving healthcare. His contributions through patents and collaboration with esteemed colleagues highlight the importance of research in developing effective therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile